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Abstract
Background
Until recently, circulating micro-RNAs (miRNAs) have attracted major interest as novel
biomarkers for the early diagnosis of coronary artery disease (CAD). This review article
summarizes the available evidence on the correlation of micro-RNAs with both the clinical and
subclinical coronary artery disease and highlights the necessity for exploring miRNAs as a
potential diagnostic and prognostic biomarker of early CAD in an adult population.

Methods
A systematic literature analysis and retrieval online systems Public/Publisher MEDLINE/
Excerpta Medica Database /Medical Literature Analysis and Retrieval System Online,
(PUBMED/EMBASE/MEDLINE) search were conducted for relevant information. Search was
limited to the articles published in English language and conducted on humans, January 2000
onwards. We excluded studies of heart surgery, coronary artery bypass grafting (CABG),
angioplasty and heart transplant. Eighteen studies met the inclusion criteria.
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Results
Seven out of 18 studies were multivariate, i.e. adjusted for age, gender, body mass index (BMI),
smoking, hypertension, diabetes, and blood lipid profiles, while the remaining twelve studies
were univariate analysis. Different sources of miRNAs were used, i.e. plasma/serum,
microparticles, whole blood, platelets, blood mononuclear intimal and endothelial progenitor
cells were investigated. Fourteen out of 18 studies showed up-regulation of different miRNA in
CAD patients and in vulnerable plaque disease. Four out of 18 studies showed both the upregulation and down-regulation of miRNA in the population, while only three studies showed
down-regulation of miRNA. Various sources and types of miRNA were used in each study.

Conclusion
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This review gives an extensive overview of up-regulation and down-regulation of miRNA in
CAD and non-CAD patients. The pattern of miRNA regulation with respect to CAD/non-CAD
study subjects varies across individual studies and different parameters, which could be the
possible reason for this aberrancy. We suggest further trials be conducted in future for
highlighting the role of miRNA in CAD, which may improve both the diagnostic and therapeutic
approaches to stratifying CAD burden in the general population.

Categories: Cardiology, Family/General Practice, Internal Medicine
Keywords: mirna, coronary artery disease, association

Introduction
Heart disease is the leading cause of death for both males and females with more than half of
the deaths reported in 2009 in males [1]. Coronary heart disease is the most common type of
heart disease with 370,000 annual deaths, i.e. each minute someone in the United States dies
from a heart disease-related event [2]. Coronary heart disease alone each year costs the United
States $108.9 billion, which includes the cost of health care services, medications, and lost
productivity [3]. The total coronary artery disease (CAD) prevalence is 6.4% in US adults, which
is expected to increase approximately 18% by 2030 [4]. Most individuals aged over 60 years have
progressively enlarged deposits of calcium mineral in the plaques in their major arteries [5]. As
atherosclerosis infiltrates the arterial wall long before it causes vessel obstruction and produces
symptoms, earlier identification of this process should be part of risk prediction [6]. As such,
there is a lack of cost-effective and specific biomarkers for the early clinical diagnosis and
prognosis of CAD, and there is an immense clinical demand for specific and reliable noninvasive biomarkers for CAD.
With over 1900 MicroRNA (miRNAs) discovered in humans to date, many of them have already
been implicated in common human disorders. However, the pattern among the miRNA-disease
association remains largely unclear for most diseases. Until recently, circulating micro-RNAs
(miRNAs) have attracted major interest as novel biomarkers for the early diagnosis of CAD [7].
MiRNAs are a class of small (~22 nucleotides long), highly specific, endogenous, singlestranded, non-coding RNAs that regulate the expression of target genes by binding to the 39
untranslated regions and degrading or inhibiting the translation of messenger ribonucleic acid
(RNA) (mRNAs) [8]. Studies have shown miRNAs' involvement in the timing of cell death and
cell proliferation, hematopoiesis, and other normal cellular homeostasis [9-10]. Various
miRNAs are expressed in a tissue-specific manner and thus may regulate tissue-specific
functions. This review article summarizes the available evidence correlating micro-RNA,
clinical and subclinical CAD and further highlights the necessity for exploring the potential of
micro-RNAs as useful diagnostic and prognostic biomarkers for early CAD in the adult
population.

Materials And Methods
A computerized search of the Public/Publisher MEDLINE/ Excerpta Medica Database /Medical
Literature Analysis and Retrieval System Online/Excerpta Medica Database
(PubMed/Medline/EMBASE) database was done with the keywords and medical subject
headings (MESH) terms such as “micro RNA,” “coronary artery disease,” “cardiovascular disease
(CVD),” “Subclinical CVD,” “coronary artery calcium and micro RNA,” "miRNA and high
sensitivity C- reactive protein (hs-CRP),” “miRNA and coronary intimal thickness,” and
“miRNA and pulse wave velocity.” We included all the literature that was published from
January 1, 2000, until January 1, 2017. The search was limited to articles published in the
English language. Included studies were cross-sectional, case-control or prospective in design
and conducted in adult populations (Figure 1). CAD subjects diagnosed by symptoms, imaging,
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cardiac enzymes, electrocardiogram (EKG), diagnostic angiography or stress testing were
included. We excluded studies with CAD patients who have had heart surgery, coronary artery
bypass graft (CABG), angioplasty, and heart transplant. We also examined the references of all
studies from the initial search for additional references. Demographic data was extracted from
each study and results were collaborated into tables.

FIGURE 1: Detailed literature analysis- CAD and miRNA
association

Results
A total of 18 clinical studies has been included in the review after a thorough analysis of the
literature. Overall, there were 1720 subjects. The majority of the studies included were done in
China, which was 11 in number, while two studies from Japan, one from the USA, one from
Norway, one from Netherlands, one from the UK and one from Germany were included (Table
1). All the studies had the same outcome, which was CAD. Studies were further divided into two
groups of microRNA up-regulation and down-regulation. There were four studies that checked
for both up-regulation and down-regulation of microRNA.

Type
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Serial#

Author, Year, Study

Study Population Characteristics

Country

Population

1

2

3

4

5

6

7

8

9

CAD: A: 76±2; M: 3 (60%)

(n=5), ACS (n=5)

66±4; M 5 (100%)

Sayed, et al., 2015 [11]; CAD

CAD: A: 53 (49–57); M: 38 (58.4%) Non-CAD: A: 53

(n=65), Non-CAD (n=32)

(49–57); M: 16(50%)

Sayed, et al., 2015 [12]; CAD

CAD: A: 72.97 ± 4.28; M: 18 (67.5%) Non-CAD: A:

(n=37), Non-CAD (n=20)

71.7 ± 5.2, M: 10(50%)

Zhou, et al., 2015 [13]; CAD

CAD: A 64.70± 6.79 M: 43 (64.2%) Non-CAD: A:

(n=67),Non-CAD (n=67)

63.69± 5.96 M: 32 (47.8%)

(n=90), Non-CAD (n=70)

Not Given
CAD A: 67±11; M: 32 (100%) Non-CAD: A 62±8; M:

(n=32), Non-CAD (n=20)

20 (100%)

(n=56), Non-CAD (n=54)
Li, et al., 2013 [17]; PreCAD(n=12), Non-CAD (n=12)

China

China

China

China

Age/Sex matched in pre CAD and Non CAD.

China

(UA) (n=45), Non-CAD (n=37)

59±6, M: 22 (59.4%)

(n=100)

China

China

CAD (UA): A: 63±12; M: 25 (55.5%) Non-CAD:

HLD+CAD (n=155), non-HLD

China

Not Given

Ren, et al., 2013 [18]; CAD

Guo, et al., 2012 [19];
10

ACS: A:

Han, et al., 2015 [15]; CAD

Zhu, et al., 2014 [16];CAD

HLD+CAD: A: 65.3 ± 11.0; M: 105 (67.7%) NonCAD: A 63.0 ± 10.7; M: 35 (70%)

China

China

Weber, et al., 2011 [20];
11

CAD (n=10), Non-CAD

Outcome

Study

Diehl, et al.,2011 [8]; CAD

Liu, et al., 2015 [14];CAD

of

Age and sex matched

USA

(n=15)

Case
Control
Case
Control
Case
Control
Case
Control
Case
Control
Case
Control
Case
Control
Case
Control
Case
Control
Case
Control

Case
Control

CAD

CAD

CAD

CAD

CAD

CAD

CAD

CAD

CAD

CAD

CAD

Sondermeijer, et al., 2011
12

[21]; Pre CAD (n=40), Non-

Age matched and males only; controls > 20 yr

CAD (n=40) ASCL (n=27),

younger, sex unknown

Netherlands

Case
Control

CAD

family(n=40)
Fichtlscherer, et al., 2011
13

[22];CAD (n=67), Non-CAD
(n=31)
Taurino, et al., 2010 [23];

14

CAD (n=12), Non-CAD
(n=12)

Cohort; CAD: A: 67.69 ± 11.07; M: 25 (69.4%)
Non-CAD: A: 32.18 ± 8.78Male: 6 (35.3%); VC;
CAD: A: 68.06 ± 9.66; M: 21 (68%) Non-CAD: A:

Germany

UAP (n=25), SAP (n=25),

Control

CAD

39.28 ± 17.52; M: 5: (36%)
CAD: A: 66±11; M: 12 (100%) Non-CAD: A: 59 7;
M: 12 (100%)

UK

Hoesktra, et al., 2010 [24];
15

Case

Age, sex, ethnically, smoking matched

Non- CAD (n=20)

Norway

Case
Control

Case
Control

CAD

CAD

Takahashi, et al., 2010 [25];
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16

17

Stable CAD (n=66), Non-

CAD: A: 66.2±9.5, M: 52 (79%) Non-CAD: A:

CAD (n=33)

64.2±10.3, M: 26 (79%)

Li, et al., 2010 [26]; AO
(n=104), Non-AO (n=105)
Minami, et al., 2009 [27];

18

Stable CAD (n=44), NonCAD (n=22)

Japan

Case

CAD

Control

Age Matched

China

CAD: A 66.1±12.8; M: 36 (82%). Non-CAD: A: 64.5
± 8.5, M: 17 (77%)

Japan

Case
Control
Case
Control

CAD

CAD

TABLE 1: Demographics table
A :Age, M: Male, CAD: Coronary Artery Disease, AP: Atherosclerotic Plaque, Pre: Premature, UA: Unstable Angina, HLD:
Hyperlipidemia, ACS: Acute Coronary Syndrome, ASCL: Atherosclerosis, VC: Validation Cohort, UAP: Unstable Angina Pectoris,
SAP: Stable Angina Pectoris, AO : Arteriosclerosis Obliterans

Up-regulation and microRNA
A total of 15 studies reported up-regulation of micro RNAs in patients with CAD. Ten
studies out of the 15 used plasma as the source while two studies used peripheral blood
mononuclear cells as the source, one study used microparticles (MP) from plasma, one
study used endothelial progenitor cells (EPC) and one study used platelets. The majority of
the studies employed quantitative reverse transcription polymerase chain reaction (QRTPCR) for mircoRNA analysis while only one study employed Kyoto encyclopedia of genes
and genomes (KEGG) method for microRNA analysis (Li, et al. 2013). All studies reported
that there is up-regulation of specific miRNA in relationship to CAD. Univariate analysis
was done in nine of the 15 studies, while remaining studies adjusted for age, sex, highdensity lipoprotein (HDL), low-density lipoprotein (LDL), aspartate aminotransferase (AST),
alanine aminotransferase (ALT), hypertension HTN etc in their analysis (Table 2 ).

Strength of
Serial
#

Name of

MicroRNA

Author; Year

(miR or

of Study

miRNA)

MicroRNA:

MicroRNA

Regulation

Analysis

Association (Odds
Source

ratio, Relative Risk or

Comments

Regression Analysis)

UpmiR 19 miR
1

Diehl, et al.

21 miR 146

2012 [8]

miR 155
miR 223

regulated:
miR 19
miR 21

QRT-PCR

miR 146

MP

ACS vs CAD

miR

from

21 P=0.042 miR 146a

plasma

P=0.003

Univariate Analysis

miR 155
miR 223

2

Sayed, et
al., 2015 [11]

miR149 miR

Up-

424 miR

regulated:

765

miR 765

QRT-PCR
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Non-CAD vs. CAD

Adjusted for age,

(Adjusted) miR 149

gender, TC, TAG, HDL-

95% CI 0.894 to 0.983

C, LDL-C, systolic blood

Serum/

p= <0.0001 miR 424

pressure, diastolic blood

Plasma

95% CI 0.863 to 0.975

pressure, AST, ALT,

p = <0.0001 miR 765

creatinine, LVEF, DM,

5 of 14

95% CI 0.939 to 0.996

smoking, HTN and

p=0.0001

medications
Adjusted for subjects
with similar age, gender,
total cholesterol, total

3

Sayed, et al.,

miR 149

2015 [12]

miR 765

Stable/unstable CAD

Upregulated:

QRT-PCR

miR 765

Serum/

vs Non-CAD

Plasma

(Adjusted) miR 765 p=
< 0.001

glyceride, HDL, LDL,
systolic blood pressure,
diastolic blood pressure,
AST, ALT, creatinine,
cardiac troponinI, CKMB, LDH, LVEF, DM,
smoking, HTN, and
medications
Multivariate analysis (no

4

Zhou, et al.,

miR206

2015 [13]

miR574/5p

Up-

CAD vs Non-CAD

significant differences

regulated:

(Adjusted) miR 206 –

between two groups

miR 206

95% CI: (0.508-0.706)

including HTN, DM,

miR

QRT-PCR

Plasma

miR 574/5p – 95% CI:

smoking history, age,

574/5p

(0.609- 0.787)

gender, HDL-C, TAG,
LDL-C and TC)

Unadjusted miR

5

Up-

133a/3p 95% CI 0.55-

Univariate Analysis

regulated:

0.82 p = 0.0096 miR

Matched for sex, DM,

miR

134 95% CI 0.54-0.82

and age. A key feature in

miR 2861

133a/3p

p= 0.015 miR 191/3p

vasculature calcification

miR 3135b

miR 134

95% CI 0.58-0.83p=

is the osteogenic

miR191/3p

miR

Liu, et al.,

miR133a/3p

191/3p

0.0046 miR 223 95%

transition of SMCs miR

Serum/

CI 0.47-0.74p= 0.13

2015 [14]

miR1229/5p

miR 223

2861 might function as

Plasma

miR 1229-5p 95% CI

an enhancer of

miR134
miR3679/5p

miR

0.54-0.83 p= 0.015

osteogenic

1229/5p

miR 286195% CI

differentiation of SMCs.

miR223

miR 2861

0.61-0.87 p= <0.001

The increased

miR 3135b

miR 3135b95% CI

circulating miR 2861

miR

0.61-0.86 p= <0.001

level may reflect CAC

3679/5p

miR 3679/5p95% CI

progression.

QRT-PCR

0.49-0.79 p = 0.06
CAD vs Non-CAD

Up6

Han, et al.,
2015 [15]

miR 21a

regulated:

miR 23a

miR 21

miR 34a

miR 23a

miR-34a, miR-21, and
QRT-PCR

Serum/

miR-23a that are

Plasma

differentially
expressed in CAD

miR 34a

7

Li, et al., 2013
[16]

UpmiR 526b

regulated:
miR 526b

Univariate Analysis

plasma p=<0.01
Pre CAD vs Non-CAD
MiRNA by

Serum/

(Adjusted) miR 526b

KEGG

Plasma

p=0.00072,

Univariate Analysis

p=0.003215
CAD (UA) vs Non-

2017 Malik et al. Cureus 9(4): e1188. DOI 10.7759/cureus.1188

6 of 14

CAD (Adjusted) miR
21OR 2.488 95% CI
(1.173, 5.277) p=
<0.017 miR 25 OR
2.036 95% CI (1.048,

Up-

3.955) p =<0.036 miR

regulated:

8

miR 21 miR

miR 21

25 miR 92a

miR 25

Ren, et al.,

miR 106b

miR 92a

2013 [18]

miR 126

miR 106b

miR 451

miR 126

miR 590/5p

miR 451

92a OR 2.611 95% CI

QRT-PCR

Serum/
Plasma

(1.110, 6.144) p =<

Adjusted for age, sex,

0.028 miR 106b OR

HTN, dyslipidemia, DM,

2.389 95% CI (1.158,

smoking status, and the

4.927) p= <0.018 miR

use of statins and anti-

126 OR 1.882 95% CI

platelet drugs)

(1.140, 3.108) p =

miR

<0.013 miR 126 OR

590/5p

1.882 95% CI (1.140,
3.108) p =<0.013 miR
451 OR 4.609 95% CI
(2.171, 9.782) p =
<0.001 miR 5905p OR
2.67895% CI (1.226,
5.849) p =<0.013
HLD+CAD vs Non-

Up9

Guo, et al.,

miR 122

regulated:

2012 [19]

miR 370

miR 122

QRT-PCR

CAD miR 122 OR 1.08

Adjustment for age,

Serum/

95 % CI 1.01–1.16 p =

gender, BMI, smoking,

Plasma

0.034 miR 370 OR

HTN, DM, and blood

1.05 95 % CI 1.01–1.12

lipid profiles

miR 370

p = 0.022
Sondermeijer,
10

et al.,2011
[21]

UpmiR 340

regulated:

miR 624

miR 340

Pre CAD vs Non-CAD
QRT-PCR

Platelets

miR 624

miR-340/ miR624 95%
CI: 0.59–0.83, p=
<0.002

Univariate Analysis In

miR 17 miR

11

92a miR

Up-

Fichtlscherer,

126 miR

regulated:

et al., 2010

133a miR

miR 133a

[22]

145 miR

miR 208a

CAD vs Non-CAD
QRT-PCR

Plasma/
Serum

155 miR

miR133a95% CI (5.226.35,3.94-6.10) p=0.16
miR208a 95% CI(5.726.74, 4.91-6.61) p=0.29

208a

12

Hokestra, et

miR 135

al., 2010 [24]

miR 147

Univariate Analysis

patients with stable
CAD, vascularderivedMiRNAs were
significantly downregulated, whereas
musclederivedMiRNAs
tended to be higher.

Upregulated:

QRT-PCR

miR 135

PBMCs

CAD vs Non-CAD miR
135a p=<0.001

Univariate Analysis

Adjusted for age, sex,
culprit lesion, fasting
glucose, HbA1C, LDL
cholesterol, highsensitive CRP, and
history of HTN, DM, and
corrected CAD. Marked
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TLR4 expression in
atherosclerotic plaques,
oxidative stress
upregulates

Up13

Takahashi, et
al., 2010 [25]

miR146a/b

regulated:
miR146a/b

QRT-PCR

PMBC

CAD vs Non-CAD miR

macrophage TLR4

146a/b

expression, perhaps an

p=<0.01

association between
TLR4, inflammation and
coronary
atherosclerosis.
Activation of TLR4
signal may induce miR146a/b expression as a
negative regulator and
induce progression of
coronary
atherosclerosis.
Up-

14

miR 21 miR

regulated:

Vessel

Li, et al., 2010

27b miR

miR 21

Intima

[26]

130, miR

miR 27b

210

miR 130

QRT-PCR

and
Serum

AO vs Non-AO miR
21/27b/130/210 p=

Univariate Analysis

<0.05

miR 210
Levels of miR 221 and

Up15

Minami, et al.,

miR 221

regulated:

2009 [27]

miR 222

miR 221

miR 222 were higher in
QRT-PCR

miR 222

EP

CAD group than in

Univariate Analysis

non-CAD group
(p<0.01)

TABLE 2: MicroRNA up-regulated studies
QRT-PCR: Quantitative Reverse Transcription Polymerase Chain Reaction, CAD: Coronary Artery Disease, DM: Diabetes Mellitus,
HTN: Hypertension, TC: Total Cholesterol, TAG Triacylglycerols, HDL-c: High Density Lipoprotein Cholesterol, LDL-c: Low Density
Lipoprotein Cholesterol, AST: Aspartate Aminotransferase, ALT: Alanine Transaminase, LVEF: Left Ventricle Ejection Fraction, CKMB: Creatine Kinase Myocardial B fraction, LDH: Lactate Dehydrogenase, BMI: Body Mass Index, HLD : Hyperlipidemia, ACS:
Acute Coronary Syndrome, KEGG: Kyoto Engenomes, SMCS: Smooth Muscle Cells, HBA1C: Hemoglobin A1C, CRP: C-Reactive
Protein, TLR: Toll Like Receptor, AO: Arteriosclerosis Obliterans. EP: Endothetial Progenitor Cells, MP- Microparticles

Various different microRNA subtypes were studied with overlapping of the similar subtypes
across the studies. Sayed, et al. did two different studies in two different age groups namely 4060 and geriatric population. MicroRNA 756 was significantly up-regulated in both the middleaged and elderly with a potential to be considered as a non-invasive biomarker in this
population. Regulation of microRNA 223 was studied by Liu, et al. in 2015 and Diehl, et al. in
2012 in two case-control studies in China. Both the studies were not able to find a significant
relationship between CAD and MiR 223, respectively. MiR 21 upregulation was tested in three
of the studies: by Ren, et al. 2013, Diehl, et al., 2012 and Li, et al., 2010. Ren, et al. reported that
the relationship of MiR 21 to CAD had the OR 2.488 CI 95% (1.173-5.277) p =0.017, while Diehl,
et al. reported it to be p =0.042 and Li, et al. reported it to be p =0.05. MiR 92a and 126 were
under study by two authors, namely, Fichtlscherer, et al. (2010) and Ren, et al. (2013). Ren, et
al. reported that miR 92a and 126 when compared with CAD and non-CAD subjects had the OR
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2.611; CI 95% (1.110-6.144) p =0.028 and OR 1.882;CI 95% (1.140-3.108) p =0.013, respectively.
Fichtlscherer, et al. reported MiR 92a and 126 up-regulation had no significant relationship
with CAD when compared with non-CAD patients. MiR 146a was also studied by two authors
Takahashi, et al. and Diehl, et al. Both the authors were able to find a relationship of the upregulation of miR 146a. Lastly, miRNA 155 was also studied by two authors, namely,
Fichtlscherer, et al. and Diehl, et al. Neither studies found conclusive results for the
significance of this biomarker with CAD subjects when compared with non-CAD subjects.

Down-regulation and mircoRNA
A total of seven studies worked on the down-regulation of microRNA. All of the studies
employed QRT-PCR as the method of analysis for detection of microRNA. Three studies used
plasma as the source. Peripheral blood mononuclear cells were used by two studies. Two studies
used whole blood as the source and one study used pericardial fluid and coronary arteries
intima. All the studies reported down-regulation of microRNA in patients with CAD compared
with non-CAD patients. The adjusted parameters were same as the up-regulation studies used.
MicroRNA subtypes which overlapped in the reviewed studies are miR 149, miR 155, and miR
145. MicroRNA 149 was studied by Sayed, et al. in 2015, in two different studies on two
different age groups, which were 40-60 and a geriatric population. MicroRNA 149 was found to
be down-regulated in both middle-aged and the geriatric patients. MicroRNA 155 was studied
by four different authors namely, Hao, et al. 2014, Zhu, et al. 2014, Weber, et al. 2011 and
Fichtlscherer, et al. Hao, et al. [28] reported 95% CI (6.92±0.93, 5.08±1.55) p =0.017, Zhu, et al.
reported by Spearmen correlation analysis r =-0.663, p <0.001. Weber, et al. reported relation to
be significant with the p =0.002 while Fichtlscherer, et al. reported that there was no significant
relationship of microRNA 155 to CAD when compared to non-CAD patients (Table 3).

1.

Name of

MicroRNA

Author; Year

(miR or

of Study

miRNA)

Sayed, et al.,

miR149 miR

2015 [11]

424 miR 765

Strength of
MicroRNA:

MicroRNA

Regulation

Analysis

Source

Association (Odds
ratio, Relative Risk or

Comments

Regression Analysis)

Down Reg:
miR 149 miR

QRT-PCR

424

Non-CAD vs. CAD

Adjusted for age,

(Adjusted) miR149 95%

gender, TC, TG, HDL-C,

CI ( 0.894-0.983)

LDL-C, systolic blood

Serum/

p=0.0001 miR 424 95%

pressure, diastolic blood

Plasma

CI (0.863-0.975)

pressure, AST, ALT,

p=0.0001 miR 765 95%

creatinine, LVEF, DM,

CI (0.939-0.996)

smoking, HTN and

p=0.0001

medications.
Adjusted for subjects
with similar age, gender,
total cholesterol, total
glyceride, HDL, LDL,

2.

Sayed, et al.,

miR149 miR

Down Reg:

2015 [12]

765

miR 149

QRT-PCR

Serum/
Plasma

CAD vs Non CAD

systolic blood pressure,

(Adjusted) miR 149

diastolic blood pressure,

p=0.001

AST, ALT, creatinine,
cardiac troponinI, CKMB, LDH, LVEF, DM,
smoking, HTN, and
medications.
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Correlation of miR-155

3.

Zhu, et al.,
2014 [16]

miRNA 155

Down Reg:
miR 155

QRT-PCR

PBMC

levels in PBMCs to

Adjusted ( miR-155 was

Gensini scores in all

correlated to multiple

patients (n=110).

metabolic and CAD RF,

Spearman correlation

including age, HTN, TC,

analysis showed a

HDL-C, LDL-C,

negative correlation

Smoking, ACEI, statins,

between miR-155

and CRP, but not sex,

expression and the

hereditary and DM or

Gensini score in all

Impaired Glucose

patients; r = –0.663,

Tolerance.

p=0.001.

4.

Weber, et al.,
2011 [20]

miR 19a miR

Down Reg :

29a miR

miR 19a miR

30e/5p miR

29a miR

145 miR 150

30e/5p miR

miR 155 miR

145 miR 150

181d miR

miR 155 miR

222 miR 342

181d miR 222

miR 378 miR

miR 342 miR

584

378 miR 584

CAD vs Non-CAD miR

Univariate Analysis As

19a p= 0.012 miR

whole blood samples

29a p=0.012 miR

were studied, thus

30e/5p p= 0.02 miR 145 miRNA profile likely
QRT-PCR

Whole

p= 0.008 miR 150 p=

reflects intracellular and

blood

0.006 miR 155 p=

extracellular miRNAs

0.002 miR 222 p=

levels, in contrast to

0.001 miR 342 p=0.001

exclusively extracellular

miR 378 p= 0.001 miR

miRNAs that would be

584 p= 0.036

detected in plasma.

CAD vs Non-CAD
miR 17 95% CI(9.06miR 17 miR
Fichtlscherer,
5

et al., 2010
[22]

92a miR 126
miR 133a
miR 145 miR
155 miR
208a

10.97,5.42-8.29)

Down Reg:

p=0.001 miR 92a 95%

miR 17 miR
92a miR 126

QRT-PCR

miR 145 miR

Plasma/

CI (9.48-11.30,7.07-

Serum

9.75) p= 0.01 miR 126
95% CI (9.86-12.02,

155

6.21-9.03) p=0.001 miR
145 95% CI (3.87-5.57,
4.81-5.90) p= 0.16

Univariate Analysis In
patients with stable
coronary artery disease,
vascular-derived
miRNAs were
significantly downregulated, whereas
muscle derived miRNAs
tended to be higher.

CAD vs Non-CAD miRTaurino,
6

et al., 2010
[23]

Down Reg :
miR140/3p

miR 140/3p

miR182

miR 182 miR

140-3p control vs. CAD
QRT-PCR

Whole

p=0.002 miR-182

blood

control vs. CAD p=

92a/b

Univariate Analysis

0.001 miR-92a/b
control vs. CAD p=0.01

7

Hoesktra, et

miR 135 miR

Down Reg:

al., 2010 [24]

147

miR 147

QRT-PCR

PBMC

CAD vs Non-CAD miR
147 p=<0.01

Univariate Analysis

TABLE 3: Down-Regulated microRNA studies
Reg: Regulated, QRT-PCR: Quantitative Reverse Transcription Polymerase Chain Reaction, CAD: Coronary Artery Disease, DM:
Diabetes Mellitus, HTN: Hypertension, TC: Total Cholesterol, TAG: Triacylglycerols, HDL-c: High Density Lipoprotein Cholesterol,
LDL-c: Low Density Lipoprotein Cholesterol, AST: Aspartate Aminotransferase, ALT: Alanine Transaminase, LVEF: Left Ventricle
Ejection Fraction, CK-MB: Creatine Kinase for Myocardial B fraction, AP: Atherosclerotic Plaque, PBMC: Peripheral Blood
Mononuclear Cells, RF: Risk Factor, CRP: C-Reactive Protein, ACEI: Angiotensin Converting Enzyme Inhibitor
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Discussion
MiRNAs have been known to have an association with the physiological and pathological
processes involved in the development of CADs such as endothelial dysfunction, inflammation,
apoptosis, angiogenesis, atherosclerosis, and neointimal hyperplasia or restenosis [7,29-31].
Our systematic review summarizes 18 articles comparing miRNAs in CAD patients. Ten
studies found miRNAs that were up-regulated (21-3135b), five studies showed miRNAs that
were both up-regulated (21-765) and down-regulated (17-222), and three studies showed downregulated miRNAs (19a-584). miRNAs derived from plasma/serum, microparticles, whole blood,
platelets, blood mononuclear intimal and endothelial progenitor cells were investigated.
Circulating miRNAs (plasma or serum) exhibit remarkable stability and are highly resistant to
plasma ribonuclease (RNase) activity due to internalization in macro vesicles and the formation
of protein-miRNA complexes and can be used as a reliable marker for both the early diagnosis
and prognosis of CAD. Therefore, the levels of individual cardiac-enriched circulating miRNAs
are related to the diagnosis and prognosis of heart diseases. Recent studies have shown the
involvement of miRNAs in atherosclerosis, ranging from endothelial dysfunction to plaque
rupture suggesting the use of miRNA as potential biomarkers in early diagnosis of CAD [32].
miRNA upregulation or downregulation is either related to the atherosclerotic disease process
or the inflammatory compensation [21].
Sayed, et al. in elderly and Zhu, et al in middle-aged documented that miRNAs (149, 424 and
155, respectively) were down-regulated in CAD patients, Zhu, et al. postulated that miRNA 155
was downregulated because of the feedback mechanism that controls the overactivation of
immune cells and thus it is negatively correlated with coronary stenosis. Similarly,
Fichtlscherer, et al. found miRNA 155 to be downregulated in patients with CAD. Fichtlscherer
suggested that atherosclerotic lesions uptake circulating miRNAs, thereby decreasing their
levels in circulation and causing downregulation. miRNA 155 is noteworthy as it was found to
be downregulated in multiple studies which used different sources (serum plasma, whole blood,
and peripheral blood mononuclear cells (PMBC). Previously, Sondermeijer, et al. have reported
miRNA 624 and 340 to be down-regulated in the premature CAD patients [33].
Sayed, et al., Hoekstra, et al., and Ren, et al. showed an up-regulation of miRNA 765, 134-370
and 21-5905p, respectively, in the middle-aged population of unstable CAD patients as well.
Ren, et al. stated that miRNA (21-5905p) that are involved in the pathogenesis of vulnerable
plaque are mostly unregulated. In these patient populations, miRNA can be used as novel
biomarkers in the diagnosis of disease. The severity of the disease can be potentially seen by
aberrancy of miRNA in form of either up-regulation or down-regulation. Prior studies have
shown that the levels of miRNA are linked with disease severity. The up-regulated miRNA leads
to the evolution of plaque towards growth, instability, and rupture [33]. Fichtlscherer, et al. in a
prospective case control trial studied miRNA derived from endothelial, cardiac, skeletal, and
smooth muscle cells. Interestingly, in CAD patients endothelial and smooth muscle miRNAs
were up-regulated and in cardiac and skeletal muscle cells miRNA 133a/208a/155 were downregulated in the same patient population. Prior studies have also documented the differential
role of miRNA in skeletal, smooth and cardiac muscle [34]. The reason for this asymmetric
regulation is an uptake of miRNAs in cardiac muscles by atherosclerotic lesions in apoptotic
bodies and endothelial cells are exposed to inflammatory cells that can increase miRNA due to
cellular stressors (Fichtlscherer, et al). miRNA can be specifically monitored in certain disease
processes and used as prognostic markers as seen in CAD patients with diabetes, miRNA 145
being reduced compared to those without DM (Fichtlscherer, et al). For instance, Sondermeijer,
et al. showed that the platelet-derived miRNA can potentially fine-tune the expression of
specific gene products that may be involved in governing platelet reactivity. Therefore, a
dysfunctional miRNA-based regulatory system could lead to the development of serious
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platelet-related cardiovascular diseases (Sondermeijer, et al).
Studies by Zhou, et al. and Li, et al. in CAD patients reported an upregulation of plasma-derived
miRNA (140-3p/182, 206/574-5p, 134-3135b respectively). Taurino, et al. showed
downregulation of whole blood-derived miRNA 92-182 at the genetic level. Interestingly, Guo,
et al. and Minami, et al. in statin therapy CAD patients documented a significant
downregulation of miRNA 122/370 and 221/222 levels that were previously up-regulated.
Endothelial progenitor cells play an important level and in the regulation of miRNA after
treatment with lipid therapy on lipometabolism related miRNA (Minami, et al.). Similarly,
Takahashi, et al. noted a decrease in the miRNA 146 a-b levels in CAD patients in post-statin
and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) therapy
as well. In a cross-sectional study by Weber, et al., miRNA 19a-584 was also reported to be
significantly down-regulated in CAD patients post ACE/ARB therapy. The response of miRNA to
medications may provide an insight into the prognostic value of miRNA. Pharmacological
therapy has been known to have an effect through gene signaling pathway, which further
influences miRNA levels [7]. Diehl, et al. examined microparticles derived miRNA 19-223 and
documented an upregulation in acute coronary syndrome (ACS) patients. Certain miRNA are
shown to be involved in cardiac hypertrophy and angiogenesis and shown to be up-regulated in
microparticles (Diehl, et al). Interestingly, Li, et al. observed upregulation of miRNA 21-210 in
the intima of arteriosclerosis obliterans (ASO) patients. miRNA has been shown to be proangiogenic through its effects at the genetic level (Li, et al).

Limitations
Firstly, criteria for CAD participant enrolment across the studies were not
standardized. Secondly, the study cohorts were not age and sex matched. Thirdly, the
population size of different trials was very small. Fourthly, none of the included studies
prospectively analyzed a specific miRNA regulation derived from one source or from different
sources. Even specific miRNA regulation can be varied when compared across different studies
and sources of origin. The pre and post CAD miRNA levels were not mentioned by any of the
studies. Large randomized double-blinded studies are needed to eliminate population bias and
increase the statistical power of each study. Prospective case-control trials with longer followup periods may play a role in deciphering the prognostic potential for the miRNA markers in
CAD patients. Lastly, studies included did not mention specifically the number of patients on
ACE/ARBs or statins.

Conclusions
miRNA expression profile is associated with several human cardiovascular diseases, suggesting
their role as a novel class of biomarkers as well as potential treatment targets for cardiovascular
diseases. This systematic review provides a potential insight on miRNA regulations in subjects
with and without CAD and highlights the different parameters which could be the reason for
aberrant miRNA expression. Further understanding of miRNA expression may help to delineate
their role in improving both the diagnostic and therapeutic approaches to stratifying CAD
burden in the general population.
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